Abstract
We undertook a genome-wide association study of susceptibility to invasive group A streptococcal (GAS) disease combining data from distinct clinical manifestations and ancestral populations. Amongst other signals, we identified a susceptibility locus located 18kb from PAX5, an essential B-cell gene, which conferred a nearly two-fold increased risk of disease (rs1176842, odds ratio 1.8, 95% confidence intervals 1.5-2.3, P=3.2×10−7). While further studies are needed, this locus could plausibly explain some inter-individual differences in antibody-mediated immunity to GAS, perhaps providing insight into the effects of intravenous immunoglobulin in streptococcal toxic shock.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by grants awarded to T.P. from the Medical Research Council (G1100449), the European Society of Clinical Microbiology & Infectious Diseases (Research Grant 2013), the National Institute for Health Research (ACF- 2016-20-001) and the British Heart Foundation (PG/14/26/30509). In addition, the genotyping undertaken by the Kenyan Bacteraemia Study Group was funded as part of the Wellcome Trust Case Control Consortium 2 (084716/Z/08/Z, 085475/B/08/Z and 085475/Z/08/Z). The genotyping undertaken by the Oxford Vaccine Group as part of EUCLIDS was funded through the European Union’s Seventh Framework Programme (EC-GA no. 279185). A.J.M. was supported by a Wellcome Trust Clinical PhD Fellowship (106289/Z/14/Z) while A.J.M., S.J.C., D.O. and A.J.P. were supported by the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK. Additionally, M.B. was supported by a Medical Research Council Clinician Scientist Fellowship (MR/M008797/1), J.J.G. was supported by a Wellcome Trust Clinical PhD Fellowship (102342/Z/13/Z), J.A.G.S. was supported by a Wellcome Trust Senior Research Fellowship (098532), T.N.W. was supported by a Wellcome Trust Senior Research Fellowship (091758), J.C.K. was supported by a Wellcome Trust Investigator Award (204969/Z/16/Z) and A.V.S.H. was supported by a Wellcome Trust Senior Investigator Award (HCUZZ0) and by a European Research Council Advanced Grant (294557). S.S. was supported by the National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK. We thank the Oxford Genomics Centre at the Wellcome Centre for Human Genetics for generating the genotyping data, subsidized by Wellcome Trust Core Awards (090532/Z/09/Z and 203141/Z/16/Z). We also thank the Oxford Biomedical Research Computing facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the National Institute for Health Research Oxford Biomedical Research Centre with funding from the Wellcome Trust Core Award Grant Number (203141/Z/16/Z). We also acknowledge the support of the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, the National Institute for Health Research Imperial Biomedical Research Centre, London, UK, and the National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne, UK. None of these funders had any role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Moreover, the views expressed here are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
Several components of the data referred to in the manuscript are available through the European Genome-phenome Archive including: the UK Invasive GAS study data (accession number EGAS0000100342); the Kenyan Bacteraemia Study Group data (EGAS00001001756); the Pacific Islands Rheumatic Heart Disease Genetics Network data (EGAS00001001881). Other components will be submitted to the European Genome-phenome Archive over the coming months and/or for the most part be available from the authors on reasonable request.
https://www.ebi.ac.uk/ega/studies/EGAS00001003421
